Jentadueto
indicated to manage glycemic control in adults and developed to support blood glucose reduction in type 2 diabetes.
Strengths: 2.5/500mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor / Biguanide
- Pharmacological class
DPP-4 Inhibitor / Biguanide
- Contraindications
diabetic ketoacidosis; severe renal impairment; acute metabolic acidosis
- Minor side effects
nausea; diarrhoea; abdominal pain
- Moderate side effects
hypoglycaemia; headache
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Boehringer Ingelheim
- Onset Time
1–2 weeks
- Duration
continuous
- Storage instructions
Store below 30°C.
- Drug interactions
iodinated contrast media
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Not recommended.
Precautions and warnings
risk of lactic acidosis; monitor kidney function; discontinue before contrast imaging
Serious side effects
lactic acidosis — requires immediate medical attention; pancreatitis — requires immediate medical attention
Patient summary
indicated to manage glycemic control in adults and developed to support blood glucose reduction in type 2 diabetes.
Mechanism of action
Combines a DPP-4 inhibitor, which increases incretin hormone levels, with metformin, which decreases hepatic glucose production and improves insulin sensitivity, enhancing overall glycaemic control.
Jentadueto
indicated to manage glycemic control in adults and developed to support blood glucose reduction in type 2 diabetes.
Editorial Notes
- Active ingredient(s): Linagliptin, Metformin
- Listed indication(s): Type 2 Diabetes Mellitus
Available option
- 60 tablets - 2.5/500 mg1041-2-5-500-mg-17430